COVID-19 FACTS & FIGURES

Pfizer and BioNTech candidate Covid-19 vaccine showed to be 95% effective in early analysis, an even better result compared to data released last week. Moderna candidate Covid-19 vaccine showed to be 94.5% effective in early trials involving 30,000 people. Switzerland announced ICU beds reached full capacity and no extra units are available. Oxford and AstraZeneca Covid-19 vaccine test results are expected by late December.

Highlights:

  • November 19: 650,815 total new cases (+1.2%), vs 611,856 the previous day and 588,956 7-day average. Now confirmed
    56,837,990 cases worldwide (217 countries and territories) vs 52,715,297 cases last week.
  • 1,359,088 people have died (2.4% of confirmed cases) and 39,239,669 have recovered (69.0%).
  • Europe: 13,976,982 cases; 7-day avg growth of 240,676. USA: 11,715,316 cases; 7-day avg growth of 165,029.
  • Brazil: 5,983,089 cases, 7-day avg growth of 28,492. India: 9,004,325 cases, 7-day avg growth of 39,489.
  • The increase in new cases is starting to slow down, after the implementation of new lockdowns and restrictions especially in Europe. That said, new deaths reached a new high recording more than 65k fatalities in the past week.

Download the full publication below

No data was found

RELATED INSIGHTS

COVID-19 FACTS & FIGURES
Pfizer and BioNTech candidate Covid-19 vaccine showed to be 95% effective in early analysis, an even better result compared to data released last week. Moderna candidate Covid-19 vaccine showed to be 94.5% effective in early trials involving 30,000 people. Switzerland announced ICU beds reached full capacity and no extra units are available. Oxford and AstraZeneca Covid-19 vaccine test results are expected by late December.
THE FED REMAINS SILENT ON CHANGES TO QE AND CALLS FOR FURTHER FISCAL STIMULUS
As widely expected, the November meeting was rather uneventful: chair Powell seized the opportunity to reiterate the strong forward guidance on rates illustrated in September and to reassure on the capability of unorthodox measures to cushion a possible downturn of the economy.
CHINA’S NEW “DUAL CIRCULATION STRATEGY”
At the end of October, China approved its “Dual Circulation Strategy” which is the new five-year economic plan (2021 – 2025). The concept has been under discussion for quite some time and President Xi highlighted it already in May. In a nutshell, the concept promotes domestic demand as the central growth engine. It foresees more independent and resilient supply chains while at the same time it intends to further opening-up the corporate sector and financial markets.